{"filings":[{"id":760198,"accession_number":"0001628280-26-039293","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-06-01T12:59:46+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medifast Chief Legal Officer resigns; receives one-month severance of $35,648","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason L. Groves resigned as Chief Legal Officer & Corporate Secretary effective May 29, 2026; departure not due to any disagreement with the company.","Severance: lump-sum payment of $35,648.42 (one month base salary) under separation agreement signed May 31.","Company has commenced a search for a permanent replacement for the role.","Separation agreement includes 1-year non-solicitation, non-disparagement, and confidentiality covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":668317,"accession_number":"0001628280-26-038109","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-05-26T20:26:14+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Medifast appoints Nicholas Johnson as CEO; Dan Chard becomes non-executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicholas Johnson, 46, becomes CEO effective June 1, 2026; Dan Chard transitions to non-executive Chairman.","Johnson's compensation: $600K base salary, target bonus 100% of base, LTI target 250% of base (69% increase vs. prior role).","Stockholders approved Amended 2012 Share Incentive Plan, increasing authorized shares by 250,000.","All seven director nominees elected; say-on-pay and auditor ratification passed.","Johnson joined Medifast in 2018, most recently as President; prior senior roles at Nu Skin Enterprises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99657,"accession_number":"0001628280-26-029812","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q1 revenue $76M, down 34% YoY; net loss $2.1M; guides Q2 revenue $60-80M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 34.3% to $76.0M; net loss widened to $2.1M ($0.19 EPS) from $0.8M loss.","Active earning coaches dropped 44.9% to 14,000; rev per coach up 19.2% to $5,432.","Gross margin 68.1% vs 72.8% a year ago; operating loss $3.3M vs $1.3M.","Outlook: Q2 rev $60-80M, EPS loss $0.50-$1.00; FY rev $270-300M, EPS loss $1.55-$2.75.","Cash $168.9M, no debt; expects active earning coaches to continue declining in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":76044000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115800,"accession_number":"0001628280-26-019983","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Medifast Enters Cooperation Agreement with Steamboat Capital, Nominates Two Directors, CEO to Step Down June 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Medifast (MED) entered a Cooperation Agreement with Steamboat Capital Partners (beneficial owner >5%) on March 19, 2026.","Medifast will nominate Steamboat designees Parsa Kiai and Jeff Rose as independent directors at the 2026 annual meeting on May 19, 2026.","Existing directors Jeffrey Brown and Michael Hoer will not stand for reelection at the 2026 annual meeting.","CEO Dan Chard will step down on June 1, 2026, remaining Chairman; President Nicholas Johnson to succeed as CEO.","Steamboat agreed to customary standstill and voting provisions through the 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115799,"accession_number":"0001628280-26-008641","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q4 revenue falls 37% to $75.1M; net loss $18.1M, guides FY26 rev $270-300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $75.1M, down 36.9% YoY; active earning coaches down 40.6% to 16,100.","Net loss $18.1M ($1.65 EPS) includes $12.1M non-cash tax valuation allowance ($1.10/sh).","Full year 2025 revenue $385.8M (-36% YoY); net loss $18.7M (-$1.70 EPS).","Guides Q1 2026 rev $65-80M, loss $0.15-$0.70/sh; FY26 rev $270-300M, loss $1.55-$2.75/sh."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":385788000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115798,"accession_number":"0001628280-26-000235","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medifast CBOO Tyree departs Dec 31; COO Johnson promoted to President; CEO Chard to non-exec Chairman June 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Tyree (CBOO) departs Dec 31, 2025; receives $706,984 severance (salary + target bonus).","Nicholas Johnson promoted from Chief Field Operations Officer to President, effective Jan 5, 2026.","CEO Daniel Chard to transition to non-executive Chairman effective June 1, 2026; salary cut from $1M to $800K.","Chard's target bonus reduced from 115% to 100% and LTI from $4.6M to $2.4M until transition.","CFO James Maloney assumes leadership of supply chain function."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132220,"accession_number":"0001628280-25-048251","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q3 revenue down 36% to $89.4M; net loss $2.3M; coaches drop 35%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $89.4M vs $140.2M YoY; net loss $0.21 per diluted share vs $0.10 income.","Active earning OPTAVIA coaches fell to 19,500 from 30,000, due to GLP-1 competition.","Gross margin 69.5% vs 75.4% on fixed-cost de-leverage and $180 basis pts for product reformulation.","Q4 2025 guidance: revenue $65M–$80M; diluted loss per share $0.70–$1.25.","Cash & investments $173.5M; no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":310692000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148787,"accession_number":"0000910329-25-000015","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q2 revenue falls 37.4% to $105.6M; active coaches down 33%; Q3 guidance weak","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $105.6M, down 37.4% YoY; active OPTA VIA coaches 22,800 (-32.7% YoY); diluted EPS $0.22 (includes $2.0M net LifeMD gain).","Net income $2.5M vs. loss $8.2M a year ago; operating loss improved to $1.1M from $7.9M.","Cash and investments $162.7M, no debt; LifeMD stake sold during quarter.","Q3 2025 guidance: revenue $70M-$90M; diluted EPS range ($0.60) to $0.00.","Management cites ongoing client acquisition challenges and GLP-1 competition."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":221283000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167672,"accession_number":"0001628280-25-032457","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Medifast stockholders approve 550k share increase to 2012 incentive plan and re-elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Amended 2012 Plan adding 550,000 shares to the pool, totaling ~1,175,000 shares available.","All seven director nominees re-elected: Brown, Chard, Geary, Hoer, Schlackman, Thomas, Xian.","Advisory vote on executive compensation passed 3.59M for vs 2.48M against (41% opposed).","Ratification of RSM US LLP as auditor for FY2025 passed with 8.23M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167671,"accession_number":"0001628280-25-020336","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q1 2025: revenue down 34% to $115.7M, net loss $0.8M; Q2 guidance weak","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 33.8% to $115.7M; active earning coaches down 32.8% to 25,400.","Net loss of $0.8M vs. net income of $8.3M a year ago; diluted EPS -$0.07.","Gross margin held at 72.8%; operating loss $1.3M vs. operating income $7.9M.","Q2 2025 revenue guidance $85M-$105M; loss per share $0.00-$0.55.","Cash, equivalents, and investments $164.6M; no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":115728000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184957,"accession_number":"0001628280-25-006036","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q4 revenue down 38% to $119M; EPS $0.07; guides Q1 loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $119M (-37.7% YoY); active earning coaches 27,100 (-34.1% YoY).","Net income $0.8M ($0.07 diluted EPS); non-GAAP adjusted EPS $0.10.","Full year 2024 revenue $602.5M (-43.8%); net income $2.1M ($0.19 EPS).","Q1 2025 guidance: revenue $100-$120M, EPS loss $0.50 to $0.00 per share.","Cash & investments $162.3M, no debt; cites GLP-1 market headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":602463000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201547,"accession_number":"0001628280-24-045012","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.02","2.02","9.01"],"status":"ready","headline":"Medifast Q3 2024 revenue down 40.6% to $140.2M; EPS $0.10; guides Q4 revenue $100-120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $140.2M, down 40.6% YoY; net income $1.1M ($0.10 diluted EPS); adjusted EPS $0.35.","Active earning OPTAVIA coaches fell 36.3% to 30,000; average revenue per coach $4,672 (down from $5,008).","Cash $170M, no debt; credit facility canceled, saving ~$500k annual commitment fees.","Q4 2024 guidance: revenue $100-120M, diluted loss per share $0.10-$0.65."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":483460000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217553,"accession_number":"0001628280-24-034743","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q2 revenue falls 43% to $168.6M; net loss $0.75/share, guides Q3 loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $168.6M, down 43.1% YoY; active earning Coaches 33,900 (-36.2%); avg revenue per Coach $4,972 (-10.9%).","GAAP net loss $8.2M ($0.75 loss per diluted share); non-GAAP adjusted net income $10.1M ($0.92 EPS).","Q3 2024 revenue guidance $125M-$145M; diluted loss per share expected $0.05-$0.70.","Cash, equivalents and securities $163.5M; no debt; CEO cites transformation and LifeMD collaboration.","Gross margin improved to 73.2% (non-GAAP 74.8%); SG&A rose to 77.9% of revenue due to fixed-cost deleverage."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":343297000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237436,"accession_number":"0001628280-24-029369","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Medifast shareholders approve 515K share increase in incentive plan, re-elect board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2012 Share Incentive Plan, increasing share reserve by 515,000 and updating provisions.","All seven director nominees (Brown, Chard, Geary, Hoer, Schlackman, Thomas, Xian) re-elected.","Advisory say-on-pay resolution passed with 6,875,928 for (96.5% of votes cast).","RSM US LLP ratified as independent auditor for 2024 with 8,607,330 for (99.1% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237435,"accession_number":"0001628280-24-019030","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast posts 50% revenue decline to $174.7M in Q1; EPS $0.76 vs $3.67 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $174.7M, down 49.9% YoY; net income $8.3M ($0.76 diluted EPS) vs $40.0M ($3.67) in Q1 2023.","Active earning OPTA VIA coaches fell 35.6% to 37,800; revenue per coach decreased to $4,623 from $5,945.","Gross margin improved to 72.8% from 70.6% on inventory efficiencies, but SG&A as % of revenue rose to 68.3% from 55.3%.","Q2 2024 revenue guidance $150-170M; diluted EPS $0.05-$0.40, excludes LifeMD collaboration costs and investment gains/losses.","Cash and investment securities $156.4M with zero debt; company pivoting to GLP-1 weight loss support via LifeMD partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":174739000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254972,"accession_number":"0001628280-24-005673","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q4 revenue falls 43% to $191M; guides Q1 2024 revenue $155-175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $6.0M ($0.55 diluted EPS); adjusted net income $11.9M ($1.09 adjusted EPS).","Active OPTA VIA Coaches down 32.5% YoY to 41,100; revenue per coach fell 16.1% to $4,648.","Full-year 2023 revenue $1.1B, down 32.9% YoY; net income $99.4M ($9.10 diluted EPS).","Q1 2024 revenue guidance $155-175M; diluted EPS $0.25-0.95, excluding LifeMD collaboration costs.","Cash and investments $150M, no interest-bearing debt; company pivoting to medically-supported weight loss with LifeMD."],"consensus_eps_estimate":null,"consensus_eps_actual":9.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":1072054000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272444,"accession_number":"0001628280-23-041392","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast enters medically supported weight loss market with $20M LifeMD deal; ends quarterly dividend","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Medifast commits $20M to LifeMD ($10M platform contributions, $10M stock purchase) for collaboration.","Discontinues quarterly cash dividend immediately to redirect capital to technology and growth initiatives.","Launches OPTAVIA Nutrition Kit and Muscle Health Kit for medically supported weight loss patients.","Medifast cites medically supported weight loss market projected up to $100B by 2030 as rationale.","Collaboration integrates OPTAVIA coaches with LifeMD board-certified clinicians; pilot program completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272443,"accession_number":"0001628280-23-037043","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q3 revenue down 39.6% YoY to $235.9M; EPS $2.12 vs $3.27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $235.9M (-39.6% YoY); net income $23.1M (-36.2% YoY); diluted EPS $2.12 vs $3.27.","Active earning Coaches 47,100 (-28.9% YoY); revenue per Coach $5,008 (-15.1%).","FY2023 guidance: revenue $1,050M-1,070M; diluted EPS $8.65-$9.55.","Cash & investments $157.8M, no debt; declared $1.65/share dividend payable Nov 7."],"consensus_eps_estimate":null,"consensus_eps_actual":8.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":881039000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289269,"accession_number":"0001628280-23-033071","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Medifast inadvertently discloses internal target of flat revenue for FY2024; cautions not guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Internal target set in early 2023 anticipated flat revenue growth for FY2024.","Disclosure made inadvertently at an investor meeting on September 26, 2023.","Company emphasizes no final 2024 forecast yet; target subject to uncertainties.","Filed under Regulation FD to address inadvertent disclosure; no formal guidance intended.","Forward-looking statements caution numerous risks; no reliance should be placed on target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289268,"accession_number":"0001628280-23-031708","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast declares $1.65 quarterly dividend payable Nov 7, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $1.65 per share declared by board.","Dividend payable on November 7, 2023 to holders of record September 19, 2023.","Company expects to maintain quarterly dividend program, subject to board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289267,"accession_number":"0001628280-23-027839","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q2 revenue falls 34.7% to $296.2M; diluted EPS $2.77 vs $3.42","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $296.2M (-34.7%); net income $30.3M, EPS $2.77 vs $39.1M, $3.42 prior.","Active earning OPTA VIA coaches down 21.9% to 53,100; revenue per coach $5,578.","Q3 2023 guidance: revenue $220-$240M, diluted EPS $0.71-$1.32, tax rate 23-25%.","Cash $147.4M, no debt; quarterly dividend of $1.65 per share declared.","CEO cites economic headwinds, cost initiatives; new OPTA VIA ACTIVE line launched."],"consensus_eps_estimate":null,"consensus_eps_actual":6.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":645170000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310052,"accession_number":"0001628280-23-022233","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Medifast declares $1.65 quarterly dividend payable Aug 8, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $1.65 per share declared; payable Aug 8, 2023 to holders of record June 27, 2023.","All seven director nominees elected at June 14 annual meeting including Jeffrey J. Brown and Daniel R. Chard.","Stockholders approved advisory say-on-pay compensation and ratified RSM US as auditor for FY2023.","Advisory vote on executive compensation frequency set at one year as recommended by board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310051,"accession_number":"0001628280-23-020530","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Medifast to exit Hong Kong and Singapore, targets 15% growth and 15% margin by 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exits Hong Kong and Singapore operations effective July 1, 2023 due to post-pandemic economic changes.","Targets 15% annualized revenue growth and 15% sustainable operating margin by 2025.","Expects 200-300 bps of sustainable gross cost savings by 2025 via the Fuel for the Future program.","Plans to reinvest savings into technology, digital capabilities, and new product categories to triple addressable market.","CEO Dan Chard says shift allows more aggressive investment to deliver long-term growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310050,"accession_number":"0001628280-23-014561","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q1 revenue down 16.4% to $349M; guides Q2 revenue $250-270M, EPS $1.32-1.44","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $349M (-16.4% YoY); net income $40M ($3.67 diluted EPS) vs $41.8M ($3.59) prior year.","Active earning OPTA VIA coaches 58,700 (-8.1%); revenue per coach $5,945 (-9.0%).","Gross profit margin 70.6% vs 72.4% due to cost inflation and lower volumes.","Q2 2023 guidance: revenue $250-270M, diluted EPS $1.32-1.44, effective tax rate 24.5-26.25%.","Quarterly dividend $1.65/share payable May 9; cash $123.7M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":3.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":348983000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310049,"accession_number":"0001628280-23-012300","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medifast EVP Supply Chain Lauren Walker to retire effective May 4, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lauren Walker, Executive Vice President of Supply Chain, announced her retirement on March 13, 2023.","Retirement is effective May 4, 2023; the Company will assist in an orderly transition.","No successor has been named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328743,"accession_number":"0001628280-23-008303","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast declares $1.65 quarterly dividend payable May 9, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $1.65 per share declared by Board of Directors.","Payable on May 9, 2023 to stockholders of record as of March 28, 2023.","Company expects to maintain quarterly dividend program but future declarations remain at Board's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328742,"accession_number":"0001628280-23-004295","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q4 revenue down 10.7% to $337.2M; guides Q1 revenue $300-320M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $2.41, adjusted EPS $3.70; net income $26.5M vs $34.0M YoY.","Full-year 2022 revenue up 4.8% to $1.6B; GAAP EPS $12.73, adjusted EPS $14.50.","Active earning OPTA VIA Coaches 60,900 (+1.8% YoY); revenue per coach $5,538 (-12.4%).","Q1 2023 guidance: revenue $300-320M, diluted EPS $1.75-2.40; assumes 26-27% tax rate.","Cash $87.7M, no debt; quarterly dividend of $1.64/share paid Feb 7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":12.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":1598577000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346401,"accession_number":"0001628280-22-031582","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast declares $1.64 quarterly dividend payable Feb 7, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $1.64 per share declared by Medifast's Board of Directors.","Dividend payable on February 7, 2023 to stockholders of record as of December 20, 2022.","Company expects to maintain quarterly dividend program, subject to future Board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346400,"accession_number":"0001628280-22-028179","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q3 revenue down 5.6%; cuts FY2022 revenue and EPS guidance on macro headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $390.4M (-5.6% YoY); net income $36.2M ($3.27 diluted EPS). Non-GAAP adjusted EPS $3.32.","Active earning OPTA VIA Coaches 66,200 (+8.5% YoY) but revenue per coach fell 12.9% to $5,897.","Full-year 2022 revenue guidance cut to $1.51B-$1.59B from $1.58B-$1.66B; non-GAAP EPS to $11.61-$13.05 from $12.70-$14.10.","Gross margin 72.5% vs 74.3% prior year; cash $69.7M, zero debt; completed $100M ASR program.","Quarterly dividend of $1.64 per share declared; Euromonitor ranked OPTA VIA #1 U.S. weight loss program by revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":10.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1261332000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362795,"accession_number":"0001628280-22-024594","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast declares $1.64 quarterly dividend payable Nov 8, 2022","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $1.64 per share declared by Board of Directors.","Payable on November 8, 2022 to stockholders of record September 20, 2022.","Company expects to maintain a quarterly dividend program but future declarations subject to board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362794,"accession_number":"0001628280-22-020596","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q2 revenue up 15% to $453.3M, net income down 16.7%; cuts full-year guidance on macro headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $453.3M (+15% YoY); net income $39.1M (-16.7%); adjusted EPS $3.87 (-2.5%).","Active earning coaches 68,000 (+14.9%); revenue per coach $6,667 slightly above prior year.","Gross margin 71.0% vs 74.5% YoY due to customer acquisition costs and higher raw ingredient costs.","Entered $100M accelerated share repurchase; quarterly dividend $1.64/share.","Full-year 2022 guidance lowered: revenue $1.58B-$1.66B (prev. $1.78B-$1.84B); adjusted EPS $12.70-$14.10 (prev. $14.60-$16.05) due to inflation and consumer sentiment."],"consensus_eps_estimate":null,"consensus_eps_actual":7.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":870933000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382421,"accession_number":"0001628280-22-017354","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07","5.02","8.01","9.01"],"status":"ready","headline":"Medifast declares $1.64 quarterly dividend, reelects directors, and amends executive severance plan","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Stockholders elected seven directors to Medifast's board, each receiving over 8.8 million votes for.","Stockholders ratified RSM US LLP as independent auditor for 2022 with over 10 million votes in favor.","Non-binding advisory vote on executive compensation passed with 8.6 million votes for.","Board amended Executive Severance Plan, increasing severance multiples to 1.5x salary (2.5x for CEO) plus target bonus on change in control.","Declared $1.64 per share quarterly dividend payable on August 8, 2022 to shareholders of record June 28, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382420,"accession_number":"0001628280-22-016117","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Medifast ups revolving credit line to $225M, adds $100M accordion, switches to SOFR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First Amendment to Credit Agreement increased revolving commitments from $125M to $225M.","Company can further increase total revolving commitments by up to an additional $100M.","Interest rate benchmark changed from LIBOR to SOFR.","Amendment executed May 31, 2022; original Credit Agreement dated April 13, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382419,"accession_number":"0001628280-22-015819","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-06-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast launches $100M accelerated share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ASR with JPMorgan to repurchase $100M of common stock.","Initial delivery of ~480,000 shares; final settlement expected in Q3 2022.","Repurchase represents ~600,000 shares at May 31 close, about 5% of fully diluted stock.","Funded through available cash and borrowings under existing credit facility.","Approximately 1.4M shares remain available under current repurchase authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382418,"accession_number":"0001628280-22-011723","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q1 revenue up 22.6% to $417.6M; raises FY22 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $41.8M ($3.59 diluted EPS) vs $41.1M ($3.46) YoY.","Active OPTA VIA coaches grew 21.7% to 63,900; avg revenue per coach up 1.3% to $6,536.","FY22 revenue guidance raised to $1.78-1.84B (from $1.72-1.79B); EPS to $14.60-16.05.","Quarterly dividend increased 15.5% to $1.64/share; $10M share repurchase in Q1.","No interest-bearing debt; cash & securities $122.1M at March 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":417600000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400334,"accession_number":"0001104659-22-035060","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast declares $1.64 quarterly dividend payable May 9, 2022","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $1.64 per share declared by Board of Directors.","Dividend payable on May 9, 2022 to stockholders of record as of March 29, 2022.","Company expects to maintain quarterly dividend program, subject to Board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400333,"accession_number":"0001628280-22-003523","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q4 revenue $377.8M (+42.6%); FY 2021 revenue $1.526B (+63.2%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 diluted EPS $2.91 vs $2.36 YoY; net income $34.0M (+21.5%).","Active earning OPTA VIA Coaches up 35.3% to 59,800; revenue per coach $6,321.","FY 2022 guidance: revenue $1.72B-$1.79B; diluted EPS $14.50-$16.00.","Cash and investments $109.5M; no interest-bearing debt; $16.8M dividend paid Feb 8.","Repurchased $56M of stock in FY 2021; $10M in Q4 alone."],"consensus_eps_estimate":null,"consensus_eps_actual":13.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1526087000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419293,"accession_number":"0001104659-21-147628","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2021-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast declares $1.42 quarterly dividend payable Feb 8, 2022","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board declared a quarterly cash dividend of $1.42 per share.","Dividend payable on February 8, 2022 to stockholders of record as of December 21, 2021.","Company expects to maintain quarterly dividends but future declarations subject to board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419292,"accession_number":"0001104659-21-134376","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q3 revenue jumps 52% to $413M; EPS $3.56; coaches up 45%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue increased 52.3% to $413.4M; net income $42.0M, diluted EPS $3.56 (up 22.3%).","Active earning OPTA VIA coaches rose 44.9% to 61,000; revenue per coach $6,773 (up 7%).","Gross profit margin 74.3% (vs 75.2% last year); SG&A as % of revenue rose to 60.9% from 58.7%.","Full-year 2021 guidance: revenue $1.51B-$1.53B, EPS $13.27-$13.96.","Cash and investments $159.9M; declared $1.42/share dividend payable Nov 8; $26.3M share repurchases in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":10.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":1148253000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436853,"accession_number":"0001104659-21-115113","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medifast appoints Jonathan B. MacKenzie as Chief Accounting Officer effective Sept 13, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["MacKenzie succeeds James P. Maloney, who remains CFO; Maloney ceases as Interim CAO.","Annual base salary of $280,000; target annual bonus of 40% of base salary, prorated for 2021.","Cash sign-on bonus of $20,000; equity sign-on award of $25,000 in time-based deferred shares vesting ratably over 3 years.","MacKenzie previously a Managing Director at PwC Risk Assurance; no family relationships or arrangements with other officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436852,"accession_number":"0001104659-21-114255","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2021-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medifast declares $1.42 quarterly dividend, payable Nov 8 to holders of record Sep 21","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $1.42 per share declared by Board of Directors.","Payable on November 8, 2021 to stockholders of record as of September 21, 2021.","Company expects to continue quarterly dividends but subject to future Board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436849,"accession_number":"0001104659-21-112099","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K/A","filed_at":"2021-09-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medifast enters separation agreement with departing CAO Stephen Johnson; $106,962 severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CAO Stephen Johnson departed Aug 5, 2021; no disagreement with company or accounting practices.","Separation agreement provides lump-sum severance of $106,962 (24 weeks' pay).","COBRA health coverage continued through Feb 28, 2022; up to six months outplacement assistance.","Agreement includes non-compete, non-disclosure, non-disparagement, and general release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436851,"accession_number":"0001104659-21-100749","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medifast CAO Stephen K. Johnson departs; CFO Maloney assumes interim role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen K. Johnson resigned as Chief Accounting Officer effective August 5, 2021.","Departure was not due to disagreements or issues with financial statements.","CFO James P. Maloney will serve as interim principal accounting officer.","Company has initiated a search for a permanent replacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436850,"accession_number":"0001104659-21-100070","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q2 2021 revenue $394.2M (+79% YoY), EPS $3.96; FY guidance $1.425-1.525B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $394.2M, up 79.2% YoY; net income $47M (+114.1%); diluted EPS $3.96 (+112.9%).","Active OPTA VIA coaches 59,200 (+62.2%); revenue per coach $6,662 (+13.9%).","Gross margin 74.5% vs 72.4%; operating income $61.4M, up 118.5%","FY2021 guidance: revenue $1.425-1.525B, EPS $12.70-14.17.","Declared $1.42/sh dividend (pay Aug 6); $12.2M share repurchases; $125M credit facility undrawn."],"consensus_eps_estimate":null,"consensus_eps_actual":7.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":734858000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":141435142.45989305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}